ERBB2 and breast carcinoma: We summarize the treatment outcomes of T-DXd in the DESTINY-Breast04 and DESTINY-Breast06 trials, and we explore the sequence of available treatments for patients with HER2-low and HER2-ultralow advanced breast cancer.